Silverarc Capital Management, LLC Point Biopharma Global Inc. Transaction History

Silverarc Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$6.86 - $10.86 $718,770 - $1.14 Million	-104,777 Reduced 52.79%	93,700 $848,000
Q1 2023 May 15, 2023	SELL	$6.78 - $8.1 $1.37 Million - $1.64 Million	-202,335 Reduced 50.48%	198,477 $1.44 Million
Q4 2022 Feb 14, 2023	BUY	$5.72 - $9.78 $576,644 - $985,941	100,812 Added 33.6%	400,812 $2.92 Million
Q3 2022 Oct 28, 2022	BUY	$7.24 - $10.31 $2.17 Million - $3.09 Million	300,000 New	300,000 $2.32 Million
Q2 2022 Jul 25, 2022	SELL	$5.6 - $9.5 $1.15 Million - $1.94 Million	-204,679 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.46 - $8.13 $1,184 - $1,764	217 Added 0.11%	204,679 $1.63 Million
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $641,100 - $1.29 Million	132,733 Added 185.05%	204,462 $1.15 Million
Q3 2021 Nov 15, 2021	BUY	$7.42 - $11.26 $532,229 - $807,668	71,729 New	71,729 $552,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.